Autoantibodies targeting CASPR2 have been associated with various neurological syndromes, notably peripheral nerve hyperexcitability (PNH), which presents clinically with neuromyotonia and myokymia. This evidence concerns the gene CNTNAP2 and paroxysmal nocturnal hemoglobinuria.